



Contact Us

Unique Preserving Action of SYSTANE® FREE

Unique Ionic Buffer System

Every drop of SYSTANE® FREE Lubricant Eye Drops contains ions and buffers commonly used in artificial tear solutions, including borate, sorbitol, AMP† and zinc. When these ions and buffers combine they form a proprietary ionic buffer system.

Self-Preserving in the Bottle

- Home
- Dry Eye Cascade
- Educational Video
- Signs & Symptoms
- Tear Break-Up Time
- Ocular Protection Index
- Tear Film Structure
- The Role of Glycocalyx
- How Instability Occurs
- SYSTANE®
- Extends TF BUT
- Superior Lubricity
- Compatible with Restasis*
- Pre- & Post-Lens Wear Use
- SYSTANE® FREE
- A Gel in the Bottle
- Minimal Blur Protection
- Unique Preserving Action
- Clinical Data



SYSTANE® FREE utilizes this ionic buffer system to achieve its preserving action. Borate and sorbitol combine with the divalent zinc ion, creating a hostile environment for microorganisms within the solution and effectively preventing microbial growth in the bottle. 1

Preservative-Free in the Eye

When SYSTANE® FREE comes in contact with ions such as potassium and sodium that naturally occur in tears, the ionic buffer preserving system becomes inactive, providing a preservative-free solution for your dry eye patients who are sensitive to preservatives. 2,3

SYSTANE® FREE meets all preservative efficacy standards.

With its unique ionic buffer system, SYSTANE® FREE meets all USP preservative efficacy standards by its ability to kill or impede the growth of *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Aspergillus niger*, and *Candida albicans*. 1

1. Rosenthal R, Buck S, Schlech B. Rigorous microbiological testing of a multi-dose tear replacement formulation with no preservatives. Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO); May 2005.
2. Rodeheaver D, Griffin J, Hendrix C, et al. Pre-clinical evaluation of a novel artificial tear (AT) for dry eye. Presented at: 4th International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes: Basic Science and Clinical Relevance; November 17-20, 2004; Fajardo, Puerto Rico.
3. Hoffman HM, Choi JH, Clousing DP, Ubeis JL, Meadows DL. Pre-clinical in vitro testing of an artificial tear formulation with a novel preservation system. Accepted for presentation at: The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2006; Fort Lauderdale, Fla.

* Trademarks are the properties of their respective owners.

† Annemeyn® propandol